6.32
+0.11(+1.77%)
Currency In USD
| Previous Close | 6.21 |
| Open | 6.25 |
| Day High | 6.48 |
| Day Low | 6.04 |
| 52-Week High | 31.01 |
| 52-Week Low | 5.25 |
| Volume | 402,179 |
| Average Volume | 477,275 |
| Market Cap | 94.81M |
| PE | -1.33 |
| EPS | -4.75 |
| Moving Average 50 Days | 16.41 |
| Moving Average 200 Days | 19.83 |
| Change | 0.11 |
If you invested $1000 in Jasper Therapeutics, Inc. (JSPR) since IPO date, it would be worth $64.36 as of February 05, 2025 at a share price of $6.32. Whereas If you bought $1000 worth of Jasper Therapeutics, Inc. (JSPR) shares 3 years ago, it would be worth $131.94 as of February 05, 2025 at a share price of $6.32.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference
GlobeNewswire Inc.
10 hours ago
REDWOOD CITY, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mas
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria
GlobeNewswire Inc.
Jan 08, 2025 12:00 PM GMT
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose cohort at 8 weeks, multiple dosing regimens ≥120mg
Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025
GlobeNewswire Inc.
Jan 06, 2025 1:00 PM GMT
Webinar to be held Wednesday, January 8, 2025, at 8am ESTREDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a nove